Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice

Blood

Volumn 111, Issue 10, 2008, Pages 5109-5117

  Xing, Shu ^a,b   Ho, Wanting Tina ^a   Zhao, Wanming ^a,b   Ma, Junfeng ^a,b   Wang, Shaofeng ^a,b   Xu, Esong ^b   Li, Qingshan ^b   Fu, Xueqi ^b   Xu, Mingjiang ^c   Zhao, Zhizhuang Joe ^a,b  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b JILIN UNIVERSITY   (China)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; JANUS KINASE 2; THROMBOPOIETIN; VAV PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CELL COUNT; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; ERYTHROID CELL; GENE MUTATION; GRANULOCYTE; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC SYSTEM; HYPERPLASIA; MEGAKARYOCYTE; MOUSE; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; NONHUMAN; PHENOTYPE; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SPLEEN CELL; THROMBOCYTOPENIA; ANIMAL; GENETICS; MISSENSE MUTATION; TRANSGENE; TRANSGENIC MOUSE;

ANIMALS; ERYTHROPOIETIN; HEMATOPOIETIC STEM CELLS; HYPERPLASIA; JANUS KINASE 2; MICE; MICE, TRANSGENIC; MUTATION, MISSENSE; MYELOPROLIFERATIVE DISORDERS; PHENOTYPE; THROMBOPOIETIN; TRANSGENES;

EID: 46749137278     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-05-091579     Document Type: Article

References (31)

1. Talarico LD. Myeloproliferative disorders: a practical review. Patient Care. 1998;30:37-57.
2. Yavorkovsky LL, Cook P. Classifying chronic myelomonocytic leukemia. J Clin Oncol. 2001 ;19:3790-3792.
3. Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med. 2006:355:2452-2466.
4. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031-1037.
5. Baxter EJ, Scott LM, Gampbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054-1061.
6. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387-397.
7. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144-1148.
8. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779-1790.
9. Zhao R, Xing S, Li Z, et al. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem. 2005;280:22788-22792.
10. Zhao ZJ, Vainchenker W, Krantz SB, Casadevall N, Constantinescu SN. Role of tyrosine kinases and phosphatases in polycythemia vera. Semin Hematol. 2005;42:221-229.
11. Wernig G, MercherT, Okabe R, Levine RL, Lee BH, Gilliland DG. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood. 2006;107:4274-4281.
12. Lacout C, Pisani DF, Tulliez M, Gachelin FM, Vainchenker W, Villeval JL. JAK2V617F expres-sion in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood. 2006;108:1652-1660.
13. Zaleskas VM, Krause DS, Lazarides K, et al. Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F. PLoS ONE. 2006;1:e18.
14. Bumm TG, Elsea C, Corbin AS, et al. Characterization of murine JAK2V617F-positive myeloproliferative disease. Cancer Res. 2006;66:11156-11165.
15. Steensma DP, Dewald GW, Lasho TL, et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and the myeIodysplastic syndrome. Blood. 2005;106:1207-1209.
16. Jones AV, Kreil S, Zoi K, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood. 2005:106:2162-2168.
17. Scott LM, Campbell PJ, Baxter EJ, et al. The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders. Blood. 2005;106:2920-2921.
18. Jelinek J, Oki Y, Gharibyan V, et al. JAK2 mutation 1849G
19. Levine RL, Loriaux M, Huntly BJ, et al. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood. 2005;106:3377-3379.
20. Xu X, Zhang Q, Luo J, et al. JAK2(V617F): prevalence in a large Chinese hospital population. Blood. 2007;109:339-342.
21. Nussenzveig RH, Swierczek SI, Jelinek J, et al. Polycythemia vera is not initiated by JAK2V617F mutation. Exp Hematol. 2007;35:32-38.
22. Gaikwad A, Nussenzveig R, Liu E, Gottshalk S, Chang K, Prchal JT. In vitro expansion of erythroid progenitors from polycythemia vera patients leads to decrease in JAK2 V617F allele. Exp Hematol. 2007;35:587-595.
23. Ogilvy S, Elefanty AG, Visvader J, Bath ML, Harris AW, Adams JM. Transcriptional regulation of vav, a gene expressed throughout the hematopoietic compartment. Blood. 1998;91:419-430.
24. Garrick D, Fiering S, Martin Dl, Whitelaw E. Repeat-induced gene silencing in mammals. Nat Genet. 1998;18:56-59.
25. Li Z, Xu M, Xing S, et al. Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth. J Biol Chem. 2007;282:3428-3432.
26. Li Z, Xing S, Wang S, Ho WT, Zhao ZJ. Characterization of a highly effective protein substrate for analysis of JAK2(V617F) activity. Exp Hematol. 2007;35:1624-1632.
27. Scott LM, Scott MA, Campbell PJ, Green AR. Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia. Blood. 2006;108:2435-2437.
28. Vannucchi AM, Antonioli E, Guglielmelli P, et al. Clinical profile of homozygous JAK2V617F mutation in patients with polycythemia vera or essential thrombocythemia. Blood. 2007;110:840-846.
29. Larsen TS, Pallisgaard N, Møller MB, Hassel-balch HC. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis: impact on disease phenotype. Eur J Haematol. 2007;79:508-515.
30. Shide K, Shimoda HK, Kumano T, et al. Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F. Leukemia. 200822:87-95.
31. Tiedt R, Hao-Shen H, Sobas MA, et al. Ratio of mutant J AK2-V617F to wild-type JAK2 determines the MPD phenotypes in transgenic mice. Blood. 2008;111:3931-3940.